These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 18849543)

  • 1. The role of pharmacogenetics in treating central nervous system disorders.
    Patnaik M; Renda MJ; Athanasiou MC; Reed CR
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1504-9. PubMed ID: 18849543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges in the search for drugs to treat central nervous system disorders.
    Enna SJ; Williams M
    J Pharmacol Exp Ther; 2009 May; 329(2):404-11. PubMed ID: 19182069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic testing in schizophrenia and posttraumatic stress disorder.
    Ramey-Hartung B; El-Mallakh RS; Reynolds KK
    Clin Lab Med; 2008 Dec; 28(4):627-43. PubMed ID: 19059067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of pharmacogenetics in the use of CNS drugs: from drug pipeline to primary care?
    Hopkins MM; Martin PA
    Expert Rev Neurother; 2006 Dec; 6(12):1765-7. PubMed ID: 17181421
    [No Abstract]   [Full Text] [Related]  

  • 5. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
    Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Society for Neuroscience - 39th Annual Meeting. Part 2 - Novel therapies for neurodegenerative disorders and other CNS diseases.
    Al-Shamahi A; Kirkham K; Hookes L
    IDrugs; 2009 Dec; 12(12):734-7. PubMed ID: 19943211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translational CNS medicines research.
    Palmer AM; Alavijeh MS
    Drug Discov Today; 2012 Oct; 17(19-20):1068-78. PubMed ID: 22580061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug development for CNS disorders: strategies for balancing risk and reducing attrition.
    Pangalos MN; Schechter LE; Hurko O
    Nat Rev Drug Discov; 2007 Jul; 6(7):521-32. PubMed ID: 17599084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An introduction to adaptive designs and adaptation in CNS trials.
    Dragalin V
    Eur Neuropsychopharmacol; 2011 Feb; 21(2):153-8. PubMed ID: 20888739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A role for fMRI in optimizing CNS drug development.
    Borsook D; Becerra L; Hargreaves R
    Nat Rev Drug Discov; 2006 May; 5(5):411-24. PubMed ID: 16604100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adult neurogenesis pharmacology in neurological diseases and disorders.
    Taupin P
    Expert Rev Neurother; 2008 Feb; 8(2):311-20. PubMed ID: 18271715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptive design clinical trials and trial logistics models in CNS drug development.
    Wang SJ; Hung HM; O'Neill R
    Eur Neuropsychopharmacol; 2011 Feb; 21(2):159-66. PubMed ID: 20933373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of central nervous system drugs and analgesics among very old people with and without dementia.
    Lövheim H; Karlsson S; Gustafson Y
    Pharmacoepidemiol Drug Saf; 2008 Sep; 17(9):912-8. PubMed ID: 18398935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New drugs in neurology].
    Mattle HP
    Praxis (Bern 1994); 1999 Apr; 88(18):827-34. PubMed ID: 10409881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents.
    Cole PE; Schwarz AJ; Schmidt ME
    Clin Pharmacol Ther; 2012 Feb; 91(2):315-20. PubMed ID: 22218072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aligning strategies for using EEG as a surrogate biomarker: a review of preclinical and clinical research.
    Leiser SC; Dunlop J; Bowlby MR; Devilbiss DM
    Biochem Pharmacol; 2011 Jun; 81(12):1408-21. PubMed ID: 20937262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics-guided dose modifications of antidepressants.
    Seeringer A; Kirchheiner J
    Clin Lab Med; 2008 Dec; 28(4):619-26. PubMed ID: 19059066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opportunities in systems biology to discover mechanisms and repurpose drugs for CNS diseases.
    Mei H; Xia T; Feng G; Zhu J; Lin SM; Qiu Y
    Drug Discov Today; 2012 Nov; 17(21-22):1208-16. PubMed ID: 22750722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative psychology and the grand challenge of drug discovery in psychiatry and neurodegeneration.
    Brunner D; Balcı F; Ludvig EA
    Behav Processes; 2012 Feb; 89(2):187-95. PubMed ID: 22155361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.